Head-to-head evidence
H002 vs Icotinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
H002
Developed by RedCloud Bio
NCT05519293 · Phase 1/2 · status unknown
A non-randomized, open-label, sequential-cohort phase 1/2 study of H002 with an estimated 76 participants and no results posted to the registry. With no comparator arm and no posted results, this is weak evidence.
Icotinib
Developed by Betta Pharmaceuticals Co.
NCT01040780 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial with 200 participants assigned to icotinib and 199 to gefitinib, and its primary endpoint was the clinical measure of progression-free survival. Although the reported median favored icotinib, the statistical significance of the primary comparison is not stated, so the result is unclear rather than definitively positive.
Next expected readout: December 2030 · NCT06955325 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: H002's landscape · Icotinib's landscape